cortisone profile

cortisone is involved in 21 pathway(s), involving a total of 2276 unique proteins and 2748 unique compounds

ID Source	ID
PubMed CID	222786
CHEMBL ID	1499
CHEBI ID	16962
SCHEMBL ID	4888
MeSH ID	M0005219

Synonym
MLS001076142
BRD-K43736954-001-03-3
AKOS015840096
pregn-4-en-17alpha,21-diol-3,11,20-trione
delta(4)-pregnene-17alpha,21-diol-3,11,20-trione
kortison
cortison
4-pregnene-17alpha,21-diol-3,11,20-trione
CHEBI:16962 ,
17,21-dihydroxypregn-4-ene-3,11,20-trione
pregn-4-ene-3,11,20-trione, 17,21-dihydroxy-
delta(sup4)-pregnene-17alpha,21-diol-3,11,20-trione
(8s,9s,10r,13s,14s,17r)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione
NCI60_042165
PRESTWICK3_000273
cortisone [inn:ban]
cortisonum [inn-latin]
nsc 9703
einecs 200-162-4
17alpha-hydroxy-11-dehydrocorticosterone
cortisona [inn-spanish]
ai3-52938
[3h]cortisone
17alpha,21-dihydroxypregn-4-ene-3,11,20-trione
LMST02030090
EU-0100240
cortisone, >=98%
4-pregnene-17.alpha.,11,20-trione
17.alpha.,11,20-trione
cortisal
pregn-4-ene-3,20-trione, 17,21-dihydroxy-
11-dehydro-17-hydroxycorticosterone
.delta.(sup4)-pregnene-17.alpha.,11,20-trione
cortisate
wintersteiner's compound f
cortandren
cortivite
adrenalex
wln: l e5 b666 cv ov mutj a1 e1 fv1q fq
nsc-9703
pregn-4-en-17.alpha.,11,20-trione
kendall's compound
17-hydroxy-11-dehydrocorticosterone
nsc9703
reichstein fa
andreson
17.alpha.-hydroxy-11-dehydrocorticosterone
cortogen
cortistal
PRESTWICK_132 ,
cas-53-06-5
BPBIO1_000162
PRESTWICK2_000273
BSPBIO_000146
cortisone (inn)
cortisone (tn)
D07749
LOPAC0_000240
SPECTRUM5_002051
[3h]-cortisone
C00762
reichstein's substance fa
kendall's compound e
CORTISONE ,
53-06-5
17alpha,21-dihydroxy-4-pregnene-3,11,20-trione
NCGC00023939-06
NCGC00023939-05
NCGC00095935-01
smr000058334
MLS000028540 ,
PRESTWICK1_000273
PRESTWICK0_000273
SPBIO_002365
NCGC00023939-03
NCGC00023939-07
NCGC00023939-04
kendall's compound e; 4-pregnene-17alpha,21-diol-3,11,20-trione; reichstein's substance fa
C 2755
HMS2052A21
NCGC00023939-09
MLS002207137
CHEMBL1499
BMSE000663
(10r,13s,17r)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione
HMS1568H08
NCGC00023939-08
HMS2095H08
HMS3260P21
dtxsid5022857 ,
NCGC00255108-01
dtxcid102857
tox21_301440
tox21_111539
MLS001424269
HMS2235P19
CCG-101143
unii-v27w9254fz
cortisona
v27w9254fz ,
cortisonum
LP00240
cortisone [usp-rs]
prednisone impurity a [ep impurity]
cortisone [inn]
hydrocortisone impurity b [ep impurity]
cortisone [who-dd]
cortisone [vandf]
cortisone [mi]
AKOS015894868
S5869
gtpl5171
NC00393
bdbm13739
(1s,2r,10s,11s,14r,15s)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-ene-5,17-dione
SCHEMBL4888
tox21_111539_1
NCGC00023939-11
NCGC00260925-01
CS-5097
tox21_500240
W-105776
ricortex (salt/mix)
cortelan (salt/mix)
17.alpha.,21-dihydroxy-4-pregnene-3,11,20-trione
cortadren (salt/mix)
scheroson (salt/mix)
4-pregnene-17.alpha.,21-diol-3,11,20-trione
corlin (salt/mix)
17.alpha.,21.beta.-dihydroxypregn-4-ene-3,11,20-trione
.delta.4-pregnene-17.alpha.,21-diol-3,11,20-trione
pregn-4-en-17.alpha.,21-diol-3,11,20-trione
HY-17461
AC-33118
OPERA_ID_541
mfcd00003610
cortisone, certified reference material, tracecert(r)
cortisone 0.1 mg/ml in methanol
sr-01000000094
SR-01000000094-3
HMS3712H08
Q423185
DB14681
AS-11686
SDCCGSBI-0050228.P002
NCGC00023939-15
D96089
pregn-4-ene-3,11,20-trione, 17,21-dihydroxy
17,21-dihydroxy-pregn-4-ene-3,11,20-trione
UQC ,
therapeutic cortisone
cortisone (usp-rs)
hydrocortisone impurity b (ep impurity)
h02ab10
cortisona (inn-spanish)
cortisonum 30 special order
s01ba03
prednisone impurity a (ep impurity)
cortisonum (inn-latin)
cortisone, 1mg/ml in methanol

Excerpt	Reference
"Cortisone is a metabolite belonging to the corticosteroid class that is used pharmaceutically directly as a drug or prodrug. "	( Beggiato, S; Buzzi, R; Costa, S; Ferraro, L; Grandini, A; Manfredini, S; Sacchetti, G; Tedeschi, P; Valacchi, G, 2022)
"Cortisone (CRT) is a corticosteroid clinically used for the management of inflammatory diseases like colitis and other inflammatory bowel diseases."	( Ahmad, A; Ali, A; Almashjary, MN; Jori, C; Khan, R; Kumar, A; Mishra, RK; Raza, SS; Tabrez, S; Zughaibi, TA, 2023)
"Cortisone is a steroid widely used as an anti-inflammatory drug able to suppress the immune system, thus reducing inflammation and attendant pain and swelling at the site of an injury. "	( Bertolasi, V; Buzzi, R; Costa, S; Pedrini, P; Semeraro, B; Summa, D; Vertuani, S; Zappaterra, F, 2021)
"Cortisone is an injected anti-inflammatory drug that can cause painful side effects known as "steroid flares" which are caused by cortisone crystallizing at the injection site. "	( Alsop, RJ; Hub, JS; Khondker, A; Rheinstädter, MC, 2016)
"Cortisone is a highly potent inhibitor of influenza virus synthesis in the chick embryo, inducing manifest inhibition in doses of 0.1 to 1.0 microg/egg. "	( KILBOURNE, ED, 1957)
"Cortisone is an endogenous corticosteroid that has negligible intrinsic glucocorticoid activity but can be converted to the active corticosteroid cortisol by the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). "	( Cooper, C; Cooper, MS; Dennison, EM; Fall, CH; Stewart, PM; Syddall, HE; Wood, PJ, 2005)
"Cortisone was found to be a valuable aid to the therapy arsenal."	( Hollender, L; Jacobsson, S, 1980)

Excerpt	Reference
"Cortisone has a large content in rivers because of its wide range of medical applications and elimination by organisms that naturally secrete it. "	( Geng, Y; Guo, Y; Hou, L; Huang, M; Wu, Y; Zou, H, 2023)
"Cortisone has a large content in rivers because of its wide range of medical applications and elimination by organisms that naturally secrete it. "	( Geng, Y; Guo, Y; Hou, L; Huang, M; Wu, Y; Zou, H, 2023)
"Cortisone has been proposed as a useful additional biomarker for stress research. "	( Cao, C; Deng, H; Wang, L; Wang, W; Xu, H; Zhang, J, 2015)

Excerpt	Reference
"of cortisone may cause depression of resistance and may decrease the survival time for 3 to 6 days afterward."	( FINLAND, M; KASS, EH; LUNDGREN, MM, 1954)
"The cortisone caused an increase in the serum cholesterol, fatty metamorphosis of the liver, and fat emboli visible in sections of the femur and humerus."	( Reger, SI; Sweet, DE; Thompson, RC; Wang, GJ, 1977)
"Free cortisone was slightly lower in the pill group (I: 10.8 +/- 2.55 nmol/l; II 8.5 +/- 1.86 nmol/l) whereas salivary cortisone was 2.3 (I) and 4.4 (II) times higher than plasma free cortisone and tended to follow the plasma free and salivary cortisol pattern, both within and between the study groups.(ABSTRACT TRUNCATED AT 250 WORDS)"	( Benraad, TJ; Meulenberg, PM; Ross, HA; Swinkels, LM, 1987)
"The cortisone-mediated increase in intestinal sucrase activity which normally occurs by 20 days is not effected by prolonged suckling."	( Kimura, RE; Reinersman, GT, 1985)

Excerpt	Reference
"Cortisone treatment also reduced basal and insulin-stimulated glucose oxidation in adipose tissue, increased plasma glucose levels after administration of the pyruvate, the substrate of gluconeogenesis, and increased liver glycogen content."	( Fukuda, S; Goto, H; Heitaku, S; Katsumi, S; Maki, M; Nishiu, J; Sasase, T; Sotani, T; Yamamoto, H, 2023)
"Cortisone acetate treatment at 20-wk posttransplantation accelerated the ontogeny of lactase but did not alter sucrase and trehalase activities."	( Fernandez, I; Klopcic, CE; Nanthakumar, NN; Walker, WA, 2003)
"Non-cortisone-treated asthmatic patients displayed higher levels of both R- and S-salbutamol in plasma than did healthy volunteers after one single ingestion of racemic salbutamol (CMAX both comparisons P<0.05)."	( Ahlner, J; Andersson, RG; Josefsson, M; Naidu Sjöswärd, K; Schmekel, B, 2003)
"(3) Cortisone treatment caused a moderate hypercholesterolemia in normal rabbits."	( DUFF, GL; GORDON, D; KOBERNICK, SD; McMILLAN, GC, 1954)
"The cortisone treatment had thus completely suppressed immunity."	( ROBSON, JM; SULLIVAN, FM, 1957)
"Cortisone-treated mice were inoculated with vaccinia virus, and then five paintings of methylcholanthrene were applied over the site of inoculation. "	( DURAN-REYNALS, ML; STANLEY, B, 1961)
"Cortisone treatment reversed these changes noted in the ileum."	( Kalra, S; Seetharam, B; Seetharam, S; Yammani, RR, 2004)
"In cortisone-treated rabbits, a single intradermal injection of toxin produced a primary reaction of hemorrhage and necrosis in the skin at the injected site."	( GOOD, RA; THOMAS, L, 1952)
"Cortisone treatment in cholesterol-fed rabbits did not significantly affect the levels of serum lipoproteins, cholesterol concentration, or atherosclerosis produced by a 1.0 per cent cholesterol diet alone."	( CALVIN, LD; COOK, DL; DAVISSON, E; FELDSTEIN, LM; GREEN, DM; RAY, G, 1952)
"Cortisone acetate treatment which was sufficient for eggs inoculated to mature (a total of 75 or even 200 mg, from Day 5 of egg inoculation) had no effects of immunosuppression, whereas cortisone acetate treatment which was sufficient for immunosuppression (a total of 150 mg from Day -2, two days prior to the initial egg inoculation) induced some adult formation as well."	( Ito, A, 1983)
"Cortisone-treated subcutaneously injected animals did not develop a leukocytosis."	( Campbell, RS; Miller, RI, 1983)
"Cortisone treatment thus accelerates development of adult permeability characteristics in the pulmonary epithelium."	( Hemberger, JA; Schanker, LS, 1981)
"Cortisone treatment affected the ability of peritoneal exudate cells to respond to migratory inhibition after exposure to purified whole organisms of C."	( Chen, WJ; Kuo, CC; Yang, YS, 1983)
"Cortisone treatment of mice was found to lower their resistance to infection at a given spore dosage as measured by ET50 values."	( Cazin, J; Embree, RW; Kitz, DJ, 1983)
"Cortisone treatment resulted in a decrease in corticosterone output by quartered adrenals and an earlier and more marked drop in corticosterone production by whole adrenal homogenates."	( Malendowicz, LK, 1982)
"Cortisone-treated rabbits provide a new and expedient laboratory model for cryptococcal disease."	( Durack, DT; Lang, SD; Perfect, JR, 1980)
"Cortisone and T4 treatment was associated with increased rough endoplasmic reticulum and nucleolar enlargement, while GH treatment was associated with marked dilatation of the endoplasmic reticulum."	( Lebovitz, HE; McCarty, KS; McCumbee, WD, 1981)
"Cortisone treatment produced a profound leukocytosis, lymphocytopenia, and monocytopenia in the peripheral blood while decreasing by greater than 40% the number of AM obtainable by lung washings."	( Gudewicz, PW, 1981)
"In cortisone-treated mice, on the other hand, the yeasts caused mortalities, the extent of which varied according to the infecting species and the challenge dose."	( Damodaran, VN; Khan, ZU; Misra, VC; Randhawa, HS, 1980)
"Cortisone treatment attenuated these effects."	( Toth, LA, 1995)
"Cortisone treatment of rats resulted in both hyperglycemia and hyperinsulinemia."	( Almahfouz, A; Giorgino, F; Goodyear, LJ; Smith, RJ, 1993)
"In cortisone treated and diabetic groups, mild cellular reaction was observed."	( el Kadery, AA; Makled, MK; Mohamed, NH; Otifa, NM; Sabry, NM; Soffar, SA, 1994)
"Cortisone treatment of patients suffering from systemic lupus erythematosus and rheumatoid arthritis impressively normalized elevated XOD concentrations in rheumatic sera to those of healthy controls."	( Miesel, R; Zuber, M, 1993)
"Cortisone treatment of patients with rheumatoid arthritis, systemic lupus erythematosus, and polymyalgia rheumatica replenished impressively the serum concentration of Cu-thionein."	( Miesel, R; Zuber, M, 1993)
"Cortisone treatment provoked a decline in the number of microglial cells but did not modify GFAP levels in control rats which were not exposed to HI."	( Bona, E; Hagberg, H; McRae, A, 1996)
"Cortisone treatment on day 12 induced a precocious increase of H and decrease of L mRNA expression on day 15."	( Glass, J; Yeh, KY; Yeh, M, 2000)
"Cortisone pretreatment considerably enhances the mortality of young, male, streptozotocin-injected Holtzman rats. "	( Volk, BW; Wellmann, KF, 1977)
"Cortisone treatment rendered mice susceptible to killing by 22114."	( Gibb, E; Newham, HC; Richardson, MD; Warren, RC; White, LO, 1979)
"Cortisone or T3 treatment to mothers increased sucrase and maltase activity in jejunum and ileum of the offspring."	( Celano, P; Horowitz, C; Jumawan, J; Koldovsky, O; Lau, H, 1977)
"Cortisone pretreatment for four days to intact mice (10 mg/kg/day/4 days) had a significant protective effect in both males and females against arachidonate toxicity, eliminating the sex difference previously observed."	( Montalbert-Smith, M; Penhos, JC; Rabbani, F; Ramey, E; Ramwell, PW, 1979)
"Cortisone-treated Buffalo rats have been parabiosed with untreated controls of the same age. "	( Dearden, LC; Espinosa, T; Mosier, HD, 1978)
"Cortisone-treated animals expelled primary worm burdens without complication about 2 wk after steroid treatment."	( Olson, CE; Schiller, EL, 1978)
"Cortisone treatment prevented or markedly decreased this phenomenon indicating that cortisone exerts a definite inhibitory effect upon vascular permeability to antibody molecules."	( Germuth, FG; Valdes, AJ, 1978)
"Cortisone treatment of the donors of effector cells revealed that the cortisone resistant subpopulation of thymocytes, 2 days after cortisone injection, exhibited an increased cytotoxicity against target cells treated with unfractionated antiserum and its IgM fraction."	( Fuson, EW; Goodson, S; Lamon, EW; Lidin, B; Shaw, MW; Walia, AS, 1977)
"Only cortisone acetate treatment caused a true delay in ovo-implantation."	( Bennett, DR; Cochrane, RL; Powell, JG; Rathmacher, RP; Shaar, CJ; Smalstig, EB, 1977)
"Cortisone pretreatment rendered mice more susceptible to infection by A."	( Lehmann, PF; White, LO, 1975)
"Cortisone treatment of the neonate results in near-adult levels of alpha 1 mRNA expression."	( Chu, SH; Walker, WA; Zemelman, BV, 1992)
"Cortisone treatment attenuated these effects in S."	( Gardiner, TW; Krueger, JM; Toth, LA, 1992)
"In cortisone-treated rats recovering for 1-3 weeks, the FCFU census and EsMR normalized during the first posttreatment week, remained at control levels after 2-3 weeks, and exhibited a relapse in the third week which signified only partial recovery."	( Kidder, L; Simmons, DJ; Thomas, M, 1990)
"Cortisone and insulin treatments reduced WGA and enhanced UEA bindings to UN membranes."	( Babbar, HS; Jaswal, VM; Mahmood, A, 1990)
"Cortisone acetate treatment, which produced impaired cell-mediated immune function, was followed by nasal inoculation of 5 x 10(4) CFU of N."	( Aulicino, TM; Berkowitz, LB; duBouchet, L; Gombert, ME, 1990)
"Cortisone treatment was used to study non-malignant proliferation."	( Cordon, C; Newcomb, EW; Pellicer, A, 1990)
"Cortisone treatment (5 days) resulting in weight loss, hyperglycemia, and hyperinsulinemia did not affect the number, insulin binding affinity, or kinase activity of solubilized receptors activated with insulin in vitro or in vivo."	( Block, NE; Buse, MG, 1989)
"Cortisone treatment significantly stunted body wt, tail length, and tibia length."	( Jansons, RA; Mosier, HD, 1989)
"Cortisone-treated animals had a diffuse, progressive pneumonitis, but the influx of neutrophils to the lung, the serum antibody response, and the sensitization of splenocytes to L."	( Martin, TR; Schmidt, RA; Skerrett, SJ, 1989)
"Cortisone treatment (10 mg X 100 g body wt-1 X day-1 for 2-5 days) resulted in an approximate doubling of the percentage of active enzyme."	( Block, KP; Buse, MG; Mehard, WB; Richmond, WB, 1987)
"Cortisone treatment was started 24 h after testicular torsion and continued for 4 weeks."	( Amato, S; Buyuksu, C; Canda, MS; Kaplanoglu, N; Mertan, S; Sade, M, 1988)
"Cortisone treatment also resulted in the worms being located more anteriorly in the small intestine."	( De Rycke, PH; Van Haeren, C, 1986)
"Cortisone-treated animals had a normal periodicity of GH plasma concentration, but they showed a reduction in values in the range of 50 to 99 ng/ml (P less than 0.01) and an increase of values in the range of 200 to 499 ng/ml (P less than 0.025) and above 1000 ng/ml (P less than 0.05)."	( Jansons, RA; Mosier, HD, 1985)
"Cortisone-treated mice regularly developed infections after inoculation by any of the routes tested."	( Cazin, J; Lupan, DM, 1973)
"Cortisone-treated human liver tissue, obtained by needle biopsy, also shows an increase in acid alpha-glucosidase activity."	( Bourne, EJ; Clarke, K; Pridham, JB; Rowe, JJ, 1971)
"Cortisone-treated animals tolerated their allografts for at least 3 weeks."	( Hulka, JF; Lieberman, MW; Mohr, K, 1965)
"Cortisone treatment results in an increase in average parenchymal cell cytoplasmic volume from 5100 to 5800 micro(3) and a decrease in average nuclear diameter from 7.1 to 6.5 micro."	( Kimberg, DV; Loud, AV; Spiro, D; Wiener, J, 1968)
"Cortisone treatment is responsible for a 14-40% decrease in the amount of oxygen consumed per mg of mitochondrial protein when succinate, alpha-ketoglutarate, or beta-hydroxybutyrate are used as substrates, or with ascorbate and N,N,N(1),N(1)-tetramethyl p-phenylenediamine as electron donors."	( Kimberg, DV; Loud, AV; Wiener, J, 1968)
"Mice treated with cortisone yielded both the avirulent bacteria and virulent C."	( DUBOS, R; FAUVE, RM; PIERCE-CHASE, CH, 1964)
"Treatment with cortisone did not alter the antibody titres."	( Aiyar, S, 1983)
"Pretreatment with cortisone (40 mg/kg) reduced the permeability changes induced by trypsinated serum but had no significant effect on trypsin-induced leakages."	( Heideman, M; Roxvall, L; Sennerby, L, 1993)
"Treatment with cortisone up to 18 months later reactivated virus latent in the ganglia, and virus returned to the skin where it produced small but typical herpes lesions which shed virus."	( McCarthy, K; Tosolini, FA, 1975)
"2. Treatment with cortisone between 3 and 5 weeks of age markedly suppressed growth but did not inhibit GH secretion."	( Harvey, S; Scanes, CG, 1979)
"Treatment with cortisone acetate, however, markedly retarded spontaneous tumor development."	( Ben-Yaakov, M; Haran-Ghera, N; Meshorer, A, 1975)
"Treatment with cortisone significantly reduced the CSF chemotactic activity for both cell types; this reduction may contribute to the severe CSF leukopenia observed in cortisone-treated animals, which are unable to eradicate this yeast infection."	( Durack, DT; Perfect, JR, 1985)

Role	Description
human metabolite	Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metabolite	Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
glucocorticoid	Glucocorticoids are a class of steroid hormones that regulate a variety of physiological processes, in particular control of the concentration of glucose in blood.
17alpha-hydroxy steroid	The alpha-stereoisomer of 17-hydroxy steroid.
21-hydroxy steroid
11-oxo steroid	Any oxo steroid that has an oxo substituent at position 11.
20-oxo steroid	An oxo steroid carrying an oxo group at position 20.
C21-steroid	A steroid that has a structure based on a 21-carbon (pregnane) skeleton. Note that individual examples may have ring substituents at other positions and/or contain double bonds, aromatic A-rings, expanded/contracted rings etc., so the formula and mass may vary from that given for the generic structure.
3-oxo-Delta(4) steroid	A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
primary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a -CH2 (methylene) group.
tertiary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Metabolism	1496	1108
Metabolism of lipids	500	463
Metabolism of steroids	111	135
Metabolism of steroid hormones	25	37
Glucocorticoid biosynthesis	6	16
Steroidogenesis	11	42
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency	11	42
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH	11	42
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency	11	42
17-alpha-Hydroxylase Deficiency (CYP17)	11	42
11-beta-Hydroxylase Deficiency (CYP11B1)	11	42
21-Hydroxylase Deficiency (CYP21)	11	42
Corticosterone Methyl Oxidase I Deficiency (CMO I)	11	42
Corticosterone Methyl Oxidase II Deficiency (CMO II)	11	42
Apparent Mineralocorticoid Excess Syndrome	11	42
3-beta-Hydroxysteroid Dehydrogenase Deficiency	11	42
Glucocorticoid biosynthesis	14	11
Glucocorticoid & Mineralcorticoid Metabolism	0	13
Glucocorticoid and Mineralcorticoid Metabolism	0	4
Biochemical pathways: part I	0	466
Classical pathway of steroidogenesis with glucocorticoid and mineralocorticoid metabolism	3	25
Prostaglandin synthesis and regulation	0	8

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, HADH2 protein	Homo sapiens (human)	Potency	7.9433	0.0251	20.2376	39.8107	AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	7.9433	0.0251	20.2376	39.8107	AID893
endonuclease IV	Escherichia coli	Potency	0.6310	0.7079	12.4324	31.6228	AID1708
dopamine D1 receptor	Homo sapiens (human)	Potency	0.0259	0.0052	1.3022	8.1995	AID624455
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	32.8177	0.1000	20.8793	79.4328	AID488773; AID588453
pregnane X receptor	Rattus norvegicus (Norway rat)	Potency	35.4813	0.0251	27.9203	501.1870	AID651751
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	68.5896	0.0060	38.0041	19,952.5996	AID1159523
GLS protein	Homo sapiens (human)	Potency	31.6228	0.3548	7.9355	39.8107	AID624146
TDP1 protein	Homo sapiens (human)	Potency	33.4983	0.0008	11.3822	44.6684	AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	35.8558	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	9.4173	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID1259381; AID588515; AID743035; AID743036; AID743040; AID743053; AID743063
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	39.8107	0.0112	12.4002	100.0000	AID1030
progesterone receptor	Homo sapiens (human)	Potency	11.3769	0.0004	17.9460	75.1148	AID1346795
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	89.1251	0.5318	15.4358	37.6858	AID504845
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	14.8737	0.0002	14.3764	60.0339	AID588533; AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	33.6458	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	48.9662	0.0008	17.5051	59.3239	AID1159531
pregnane X nuclear receptor	Homo sapiens (human)	Potency	50.7163	0.0054	28.0263	1,258.9301	AID1346982; AID720659
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	7.7606	0.0002	29.3054	16,493.5996	AID743069
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	54.9410	0.0010	24.5048	61.6448	AID743215
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	61.6448	0.0010	19.4141	70.9645	AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	24.5412	0.0237	23.2282	63.5986	AID743222
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	37.1885	0.0355	20.9770	89.1251	AID504332
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	54.9410	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	15.4845	0.0578	21.1097	61.2679	AID1159528
peripheral myelin protein 22 isoform 1	Homo sapiens (human)	Potency	30.1313	23.9341	23.9341	23.9341	AID1967
atrial natriuretic peptide receptor 1 precursor	Homo sapiens (human)	Potency	0.7569	0.1346	10.3950	30.1313	AID1347049
chromobox protein homolog 1	Homo sapiens (human)	Potency	44.5655	0.0060	26.1688	89.1251	AID488953; AID540317
heat shock protein beta-1	Homo sapiens (human)	Potency	61.6448	0.0420	27.3789	61.6448	AID743210
flap endonuclease 1	Homo sapiens (human)	Potency	0.0019	0.1337	25.4129	89.1251	AID588795
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	61.1306	0.0006	27.2152	1,122.0200	AID743202
geminin	Homo sapiens (human)	Potency	23.7246	0.0046	11.3741	33.4983	AID624296; AID624297
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	1.2589	0.1259	12.2344	35.4813	AID1458
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	10.0000	0.0316	10.2792	39.8107	AID884; AID885
M-phase phosphoprotein 8	Homo sapiens (human)	Potency	100.0000	0.1778	24.7352	79.4328	AID488949
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	16.2710	0.0010	6.0009	35.4813	AID943; AID944
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	8.9125	1.7783	16.2081	35.4813	AID652104
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	12.2248	31.6228	AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	108.1000	0.1100	7.1903	10.0000	AID1449628
Glucocorticoid receptor	Homo sapiens (human)	IC50 (µMol)	2.3780	0.0000	0.4953	10.0000	AID625263
Glucocorticoid receptor	Homo sapiens (human)	Ki	1.0810	0.0001	0.3863	7.0010	AID625263
Glycine receptor subunit alpha-1	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.3780	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Ki	1.0810	0.0007	0.7653	7.0010	AID625263
Corticosteroid-binding globulin	Homo sapiens (human)	Ki	0.1288	0.0132	3.2481	10.0000	AID51055
Glycine receptor subunit beta	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.3780	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit beta	Rattus norvegicus (Norway rat)	Ki	1.0810	0.0007	0.7846	7.0010	AID625263
Glycine receptor subunit alpha-2	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.3780	0.0015	0.8044	5.0740	AID625263
Glycine receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Ki	1.0810	0.0007	0.7846	7.0010	AID625263
Glycine receptor subunit alpha-3	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.3780	0.0015	0.7600	5.0740	AID625263
Glycine receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Ki	1.0810	0.0007	0.7846	7.0010	AID625263
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	IC50 (µMol)	21.4000	0.0100	2.7656	10.0000	AID721754
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sex hormone-binding globulin	Homo sapiens (human)	Kd	0.3715	0.0002	0.3496	4.7863	AID318680
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
regulation of gluconeogenesis	Glucocorticoid receptor	Homo sapiens (human)
chromatin organization	Glucocorticoid receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
chromosome segregation	Glucocorticoid receptor	Homo sapiens (human)
signal transduction	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid metabolic process	Glucocorticoid receptor	Homo sapiens (human)
gene expression	Glucocorticoid receptor	Homo sapiens (human)
microglia differentiation	Glucocorticoid receptor	Homo sapiens (human)
adrenal gland development	Glucocorticoid receptor	Homo sapiens (human)
regulation of glucocorticoid biosynthetic process	Glucocorticoid receptor	Homo sapiens (human)
synaptic transmission, glutamatergic	Glucocorticoid receptor	Homo sapiens (human)
maternal behavior	Glucocorticoid receptor	Homo sapiens (human)
intracellular glucocorticoid receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid mediated signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of neuron apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
negative regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
astrocyte differentiation	Glucocorticoid receptor	Homo sapiens (human)
cell division	Glucocorticoid receptor	Homo sapiens (human)
mammary gland duct morphogenesis	Glucocorticoid receptor	Homo sapiens (human)
motor behavior	Glucocorticoid receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to glucocorticoid stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Glucocorticoid receptor	Homo sapiens (human)
neuroinflammatory response	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Glucocorticoid receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid metabolic process	Corticosteroid-binding globulin	Homo sapiens (human)
negative regulation of endopeptidase activity	Corticosteroid-binding globulin	Homo sapiens (human)
startle response	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
regulation of muscle contraction	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
neuroblast proliferation	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
protein localization	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
cell communication by electrical coupling	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
magnesium ion homeostasis	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
neuronal action potential	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
optic nerve development	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
hippocampus development	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
cerebral cortex development	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
corpus callosum development	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
neuronal signal transduction	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
neuromuscular process	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of touch	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
protein homooligomerization	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
regulation of postsynaptic membrane potential	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
axon development	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
cellular response to magnesium ion	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
regulation of presynaptic membrane potential	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
action potential	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
amino acid import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
proton transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
core promoter sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Glucocorticoid receptor	Homo sapiens (human)
RNA binding	Glucocorticoid receptor	Homo sapiens (human)
nuclear receptor activity	Glucocorticoid receptor	Homo sapiens (human)
nuclear glucocorticoid receptor activity	Glucocorticoid receptor	Homo sapiens (human)
steroid binding	Glucocorticoid receptor	Homo sapiens (human)
protein binding	Glucocorticoid receptor	Homo sapiens (human)
zinc ion binding	Glucocorticoid receptor	Homo sapiens (human)
TBP-class protein binding	Glucocorticoid receptor	Homo sapiens (human)
protein kinase binding	Glucocorticoid receptor	Homo sapiens (human)
identical protein binding	Glucocorticoid receptor	Homo sapiens (human)
Hsp90 protein binding	Glucocorticoid receptor	Homo sapiens (human)
steroid hormone binding	Glucocorticoid receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Glucocorticoid receptor	Homo sapiens (human)
estrogen response element binding	Glucocorticoid receptor	Homo sapiens (human)
androgen binding	Sex hormone-binding globulin	Homo sapiens (human)
protein binding	Sex hormone-binding globulin	Homo sapiens (human)
steroid binding	Sex hormone-binding globulin	Homo sapiens (human)
steroid binding	Corticosteroid-binding globulin	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Corticosteroid-binding globulin	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
disordered domain specific binding	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleoplasm	Glucocorticoid receptor	Homo sapiens (human)
cytoplasm	Glucocorticoid receptor	Homo sapiens (human)
mitochondrial matrix	Glucocorticoid receptor	Homo sapiens (human)
centrosome	Glucocorticoid receptor	Homo sapiens (human)
spindle	Glucocorticoid receptor	Homo sapiens (human)
cytosol	Glucocorticoid receptor	Homo sapiens (human)
membrane	Glucocorticoid receptor	Homo sapiens (human)
nuclear speck	Glucocorticoid receptor	Homo sapiens (human)
synapse	Glucocorticoid receptor	Homo sapiens (human)
chromatin	Glucocorticoid receptor	Homo sapiens (human)
protein-containing complex	Glucocorticoid receptor	Homo sapiens (human)
extracellular region	Sex hormone-binding globulin	Homo sapiens (human)
extracellular exosome	Sex hormone-binding globulin	Homo sapiens (human)
extracellular region	Corticosteroid-binding globulin	Homo sapiens (human)
extracellular space	Corticosteroid-binding globulin	Homo sapiens (human)
extracellular exosome	Corticosteroid-binding globulin	Homo sapiens (human)
extracellular space	Corticosteroid-binding globulin	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Glycine receptor subunit beta	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
endoplasmic reticulum	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
cytosol	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
apical plasma membrane	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
cell junction	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
dendrite	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
cytoplasmic vesicle	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
paranode region of axon	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
presynaptic membrane	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
neuronal cell body	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
axon initial segment	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
perikaryon	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
axon terminus	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
juxtaparanode region of axon	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
calyx of Held	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
synapse	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
postsynaptic membrane	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
anchoring junction	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
glutamatergic synapse	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
dendrite	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
paranode region of axon	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
membrane	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
synapse	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
juxtaparanode region of axon	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
neuronal cell body	Potassium voltage-gated channel subfamily A member 1	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (167)

Assay ID	Title	Year	Journal	Article
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID188016	Anti-inflammatory effect in rat granuloma assay, activity relative to hydrocortisone and hydrocortisone 21-acetate	1983	Journal of medicinal chemistry, Mar, Volume: 26, Issue:3	Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID500681	Activation of KV1.1 expressed in Xenopus laevis oocytes coexpressing Kvbeta1 assessed as increase in steady state current normalized to initial inactivating current at 500 uM by electrophysiology method	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID51052	In silico binding affinity to corticosteroid binding globulin (CBG)	1997	Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26	Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID500690	Induction of dissociation of KV1.1 T1 domain/rat Kvbeta2 I211R mutant complex at 2 mM by solid phase binding assay	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID74377	Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID126435	Relative binding affinity for mineralocorticoid receptor of rat kidney at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID500680	Activation of KV1.1 expressed in Xenopus laevis oocytes coexpressing Kvbeta1 assessed as increase in channel current at 500 uM by electrophysiology method	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID228061	Binding affinity towards human testosterone binding globulin.	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID212931	Binding affinity towards human testosterone binding globulin.	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID51059	Binding affinity to corticosteroid binding globulin	1998	Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14	Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID500682	Activation of KV1.1 expressed in Xenopus laevis oocytes coexpressing Kvbeta1 assessed as increase in steady state current normalized to initial inactivating current by electrophysiology method	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID74378	Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 4 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID74375	Relative binding affinity to glucocorticoid receptor on cytosol from liver at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID681354	TP_TRANSPORTER: transepithelial transport in MDR1-expressing LLC-PK1 cells	2003	Pharmaceutical research, Nov, Volume: 20, Issue:11	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID311367	Permeability coefficient in human skin	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID50906	Inhibition of mouse constitutive androstane receptor (mCAR) activity at 10 uM was determined as percent remaining activity	2003	Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22	Molecular determinants of steroid inhibition for the mouse constitutive androstane receptor.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1132664	Glucocorticoid activity in sc dosed bilaterally adrenalectomized rat assessed as glycogen deposition in liver administered for 5 days relative to cortisol	1978	Journal of medicinal chemistry, May, Volume: 21, Issue:5	A Fujita--Ban structure--activity analysis of 44 steroids.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID266004	Inhibition of MR-mediated transactivation of galactosidase reporter gene in HEK293 cells expressing 11betaHSD1	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
AID220020	Binding affinity towards human corticosteroid binding globulin.	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
AID162613	Relative binding affinity for progestin receptor of uterus of rabbit at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID356333	Antiedemic activity against DMSO-induced paw edema in sc dosed Albino rat	2003	Journal of natural products, Aug, Volume: 66, Issue:8	Acinospesigenin-A, -B, and -C: three new triterpenoids from Phytolacca acinosa.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID51056	Binding affinity to the corticosteroid-binding globulin (CBG) receptor.	2000	Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17	GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors.
AID39320	Relative binding affinity for androgen receptor of prostate of rat at 2 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID500691	Activation of KV1.1/Kvbeta1 complex expressed in Xenopus laevis oocytes assessed as increase in steady state current normalized to initial inactivating current at 500 uM by electrophysiology method	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1351943	Effective permeability of compound at 100 uM at pH 7.4 by PAMPA	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine "bio-oxidizable" prodrugs: Synthesis, biological evaluation and structure-activity relationship.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID127351	Binding affinity against human monoclonal antibody (mAb)-5C2	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID500684	Activation of KV1.1 expressed in Xenopus laevis oocytes assessed as increase in steady state current normalized to initial inactivating current by electrophysiology method	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID127349	Binding affinity against human monoclonal antibody (mAb)-11E6	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID318680	Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID213396	Glucocorticoid induced Tyrosine Aminotransferase activity relative to Dexamethasone	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID212920	Binding affinity against transport protein testosterone binding globulin.	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID500679	Binding affinity to KVbeta1 assessed as reduction of fluorescence by NADPH fluorescence spectrum based assay	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID212919	Binding affinity towards testosterone binding globulin is expressed as log(1/k).	1996	Journal of medicinal chemistry, May-24, Volume: 39, Issue:11	Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID51062	In silico steroid binding affinity to transport protein corticosteroid binding globulin	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID51058	Binding affinity towards corticosteroid-binding globulin (CBG)	2003	Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8	Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
AID51049	Binding affinity against corticosteroid-binding globulin	1993	Journal of medicinal chemistry, Feb-19, Volume: 36, Issue:4	Structure-activity relationships from molecular similarity matrices.
AID74374	Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 4 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID346025	Binding affinity to beta cyclodextrin	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID721753	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID74376	Relative binding affinity to glucocorticoid receptor on cytosol from liver at 4 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID23943	Diffusion constant for permeability of stratum corneum	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	The role of solvent-accessible surface area in determining partition coefficients.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID127352	Binding affinity against human monoclonal antibody (mAb)-7F2	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID500683	Activation of KV1.1/Kvbeta1 chimera deficient in conserved AKR core domain and containing N-type inactivation gate from Kvbeta1 expressed in Xenopus laevis oocytes assessed as increase in steady state current normalized to initial inactivating current at	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID500685	Activation of Kvbeta1 containing inactivation gate spliced into conserved core expressed in Xenopus laevis oocytes coexpressing KV1.1 assessed as increase in steady state current normalized to initial inactivating current at 500 uM by electrophysiology me	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID721754	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID51055	Binding affinity to human CBG receptor (corticosteroid-binding globulins)	2004	Journal of medicinal chemistry, May-20, Volume: 47, Issue:11	Comparative molecular active site analysis (CoMASA). 1. An approach to rapid evaluation of 3D QSAR.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID500686	Activation of KV1.1 expressed in Xenopus laevis oocytes coexpressing Kvbeta1 W155A mutant assessed as increase in steady state current normalized to initial inactivating current at 500 uM by electrophysiology method	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID237685	Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID74373	Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 24 hr	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis.
AID127350	Binding affinity against human monoclonal antibody (mAb)-1B3	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID455986	Permeability across human Caco-2 cells	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID51048	In silico binding affinity to human corticosteriod binding globulin	1997	Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20	Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID500688	Activation of KV1.1 expressed in Xenopus laevis oocytes coexpressing Kvbeta1 V245R mutant assessed as increase in steady state current normalized to initial inactivating current at 500 uM by electrophysiology method	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID500689	Induction of dissociation of KV1.1 T1 domain/rat Kvbeta2 complex by solid phase binding assay	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID500687	Activation of KV1.1 expressed in Xenopus laevis oocytes coexpressing Kvbeta1 W155A mutant assessed as increase in steady state current normalized to initial inactivating current by electrophysiology method	2008	Nature chemical biology, Nov, Volume: 4, Issue:11	Cortisone dissociates the Shaker family K+ channels from their beta subunits.
AID51054	Binding affinity for corticosteroid binding globulin is expressed as log(1/k)	1996	Journal of medicinal chemistry, May-24, Volume: 39, Issue:11	Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID592681	Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID212737	Binding affinity against testosterone-binding globulin (TeBG)	1993	Journal of medicinal chemistry, Feb-19, Volume: 36, Issue:4	Structure-activity relationships from molecular similarity matrices.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	15695 (89.21)	18.7374
1990's	591 (3.36)	18.2507
2000's	620 (3.52)	29.6817
2010's	499 (2.84)	24.3611
2020's	189 (1.07)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	171 (0.87%)	5.53%
Reviews	500 (2.55%)	6.00%
Case Studies	606 (3.09%)	4.05%
Observational	9 (0.05%)	0.25%
Other	18,299 (93.43%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (145)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open-label, 2-part Study Designed to Assess the Absolute Bioavailability of CORT118335 and Determine the Mass Balance Recovery, Absorption, Metabolism and Elimination, and Metabolite Profile and Identification of Metabolite Structures of [14C]-CORT1183[NCT03878264]	Phase 1	12 participants (Actual)	Interventional	2018-08-06	Completed
A Multicenter Study, Randomized, Double-blind With 2 Groups as Prove of Concept for the Treatment of ACEI Induced Angioedema With Subcutaneous Icatibant[NCT01154361]	Phase 2	0 participants	Interventional		Completed
Lipografting Versus Steroid Injections for Treatment of Primary Mild to Moderate Carpal Tunnel Syndrome[NCT03722303]	Early Phase 1	100 participants (Anticipated)	Interventional	2016-12-19	Recruiting
A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) as Front-Line Therapy for Adults With Acute Lymphoblastic Leukemia/Lymphoma[NCT03023046]	Phase 2	54 participants (Actual)	Interventional	2017-02-23	Completed
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers[NCT03816332]	Phase 1	12 participants (Actual)	Interventional	2019-11-08	Active, not recruiting
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma[NCT01856192]	Phase 2	349 participants (Actual)	Interventional	2013-08-27	Active, not recruiting
Non-surgical Treatment of Knee Osteoarthritis - a Comparison of Effects in 2200 Patients[NCT02091830]		2,262 participants (Actual)	Observational	2013-01-31	Completed
A Phase 1 Adaptive Dose, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered CORT113176 in Healthy Subjects, With an Optional Pharmacological Effects [NCT04249323]	Phase 1	110 participants (Actual)	Interventional	2020-01-27	Completed
A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone[NCT00033293]	Phase 3	53 participants (Actual)	Interventional	2004-03-15	Completed
A Phase 1, Randomized, Open-label, Crossover Study to Determine the Relative Bioavailability of Relacorilant Administered as 3×100-mg Softgel Capsules, 3×100 mg Hard Shell Capsules, and 6×50-mg Hard-shell Capsules in Healthy Adult Subjects[NCT03540836]	Phase 1	30 participants (Actual)	Interventional	2018-05-24	Completed
A Phase I Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Escalating Doses of Inotuzumab Ozogamicin (DA-EPOCH-InO) in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia[NCT03991884]	Phase 1	24 participants (Actual)	Interventional	2019-09-24	Completed
A Phase I Adaptive Dose, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacological Effects of Orally Administered CORT118335 in Healthy Subjects[NCT03315338]	Phase 1	143 participants (Actual)	Interventional	2017-09-15	Completed
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)[NCT00792948]	Phase 2	97 participants (Actual)	Interventional	2009-09-01	Active, not recruiting
A Phase I Adaptive Dose, Double-Blind, Placebo-Controlled, SAD and MAD Study to Measure the Safety, Tolerability, Pharmacokinetics and Pharmacological Effects of Orally Administered CORT125134 in Healthy Subjects[NCT03508635]	Phase 1	130 participants (Actual)	Interventional	2014-09-30	Completed
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen[NCT02481310]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2015-10-28	Active, not recruiting
A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-asparaginase) or Intravenous Oncaspar® in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (ALL)[NCT00671034]	Phase 3	166 participants (Actual)	Interventional	2008-07-21	Completed
A Pilot Study to Estimate the Safety and Tolerability of the Combination of Polatuzumab Vedotin With Dose Adjusted Rituximab, Etoposide, Cyclophosphamide, and Doxorubicin (DA-EPCH-PR) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas[NCT04231877]	Phase 1	50 participants (Anticipated)	Interventional	2020-10-27	Recruiting
A Phase II Study to Determine the Response Kinetics, Safety, and Efficacy of Brentuximab Vedotin and Nivolumab Alone and Then Combined With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone for Patients With Untreated Primary Mediastinal Large B-Ce[NCT04745949]	Phase 2	40 participants (Anticipated)	Interventional	2021-05-10	Recruiting
Stop LCNP: High Dose Steroid Therapy for Late Radiation-Associated Lower Cranial Neuropathy: A Phase I/II Dose Finding Trial and Data Registry[NCT04151082]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2019-10-31	Active, not recruiting
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults[NCT02003222]	Phase 3	488 participants (Actual)	Interventional	2014-05-19	Active, not recruiting
Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)[NCT00390793]	Phase 2	107 participants (Actual)	Interventional	2006-09-28	Active, not recruiting
A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)[NCT02807805]	Phase 2	37 participants (Actual)	Interventional	2016-10-31	Active, not recruiting
Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)[NCT01424982]	Phase 2	88 participants (Actual)	Interventional	2011-10-05	Active, not recruiting
A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)[NCT00972478]	Phase 1/Phase 2	83 participants (Actual)	Interventional	2010-11-15	Active, not recruiting
Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas[NCT03220022]	Phase 1	54 participants (Anticipated)	Interventional	2018-03-16	Recruiting
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma[NCT01193842]	Phase 1/Phase 2	107 participants (Actual)	Interventional	2010-10-06	Completed
An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose T[NCT00602641]	Phase 3	306 participants (Actual)	Interventional	2008-02-29	Active, not recruiting
Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma[NCT00408005]	Phase 3	1,895 participants (Actual)	Interventional	2007-01-22	Active, not recruiting
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-Prostatectomy[NCT02849990]	Phase 2	22 participants (Actual)	Interventional	2017-03-09	Completed
High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)[NCT00075725]	Phase 3	3,154 participants (Actual)	Interventional	2003-12-29	Completed
A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease[NCT00025259]	Phase 3	1,734 participants (Actual)	Interventional	2002-09-30	Completed
Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma[NCT04323956]	Phase 1	50 participants (Actual)	Interventional	2020-06-15	Active, not recruiting
A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAD and MAD of CORT125281 in Healthy Subjects[NCT03335956]	Phase 1	48 participants (Actual)	Interventional	2017-09-21	Completed
A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Double and Triple Hit Lymphoma, Double Expressor Lymphoma and High-Gr[NCT04479267]	Phase 2	49 participants (Anticipated)	Interventional	2020-08-21	Recruiting
Randomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer[NCT02949284]	Phase 2	90 participants (Anticipated)	Interventional	2017-06-20	Recruiting
A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)[NCT04301076]	Phase 1	30 participants (Anticipated)	Interventional	2021-08-31	Recruiting
Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate With Prednisone and Androgen Deprivation Therapy After Treatment With Docetaxel and Androgen Deprivation Therapy[NCT04267887]	Phase 2	7 participants (Actual)	Interventional	2020-05-11	Active, not recruiting
The Efficacy of Botulinum Toxin to the Flexor Digitorum Brevis Versus Corticosteroid to the Plantar Fascia for the Treatment of Refractory Plantar Fasciitis: A Randomized-Controlled Trial[NCT05367271]	Phase 2/Phase 3	65 participants (Anticipated)	Interventional	2022-08-23	Recruiting
A Randomized Study of Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone in Patients With Prostate Cancer Who Have PSA Progression After Prostatectomy and/or Radiotherapy[NCT01786265]	Phase 2	310 participants (Anticipated)	Interventional	2013-02-05	Active, not recruiting
A Pragmatic Phase II Study Evaluating Tolerability in Prostate Cancer Patients Treated With Abiraterone + Prednisone or Darolutamide[NCT06173362]	Phase 2	75 participants (Anticipated)	Interventional	2023-11-09	Recruiting
A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers[NCT05896839]	Phase 1/Phase 2	16 participants (Anticipated)	Interventional	2024-08-11	Recruiting
A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma[NCT03749018]	Phase 2	30 participants (Anticipated)	Interventional	2019-01-02	Active, not recruiting
A Phase 1 Study Combining Venetoclax With a Pediatric-Inspired Regimen for Newly Diagnosed Adults With B Cell Ph-Like Acute Lymphoblastic Leukemia[NCT05157971]	Phase 1	6 participants (Anticipated)	Interventional	2022-03-17	Recruiting
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone [NCT02143414]	Phase 2	53 participants (Actual)	Interventional	2015-06-30	Active, not recruiting
A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma[NCT02538926]	Phase 2	0 participants (Actual)	Interventional	2018-07-01	Withdrawn(stopped due to Drugs unavailable)
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia[NCT02877303]	Phase 2	80 participants (Anticipated)	Interventional	2016-11-01	Recruiting
A Prospective, Randomized Study Comparing One vs. Two Cortisone Injections for Trigger Finger[NCT00951236]		392 participants (Anticipated)	Interventional	2009-05-31	Recruiting
Impact of Obesity on the Pharmacokinetics of Anticancer Therapy in Children With High Risk Acute Lymphoblastic Leukemia (ALL)[NCT00900445]		0 participants (Actual)	Observational	2008-03-24	Withdrawn
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults[NCT02166463]	Phase 3	600 participants (Actual)	Interventional	2015-03-19	Active, not recruiting
An Open-Label, Repeat-Dose Study to Evaluate the Pharmacokinetics of Orally Administered CORT125134 Using the Current Capsule Formulation in Healthy Subjects[NCT06094790]	Phase 1	32 participants (Actual)	Interventional	2017-05-18	Completed
A Phase 1, Randomized, Open-Label, Single-Dose, Three-Way Crossover Study to Evaluate The Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects[NCT06094738]	Phase 1	30 participants (Actual)	Interventional	2020-09-19	Completed
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma[NCT05675410]	Phase 3	1,875 participants (Anticipated)	Interventional	2023-05-11	Recruiting
A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell L[NCT04799275]	Phase 2/Phase 3	422 participants (Anticipated)	Interventional	2021-05-20	Recruiting
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphom[NCT03914625]	Phase 3	6,720 participants (Anticipated)	Interventional	2019-07-03	Recruiting
Comparative, Randomized Study on the Anti-inflammatory and Regenerative Efficacy of a New Medical Device (DM) Based on Hydrolyzed Collagen Peptides in Patients With Femoro-acetabular Impingement Undergoing Hip Arthroscopy[NCT06082271]		25 participants (Actual)	Interventional	2021-05-28	Active, not recruiting
A Phase II Study of Modified VR-CAP and Acalabrutinib as First Line Therapy for Transplant-Eligible Patients With Mantle Cell Lymphoma[NCT04626791]	Phase 2	45 participants (Anticipated)	Interventional	2021-08-03	Recruiting
A Phase 1 Study of R-CHOP Plus SYK Inhibitor TAK-659 for the Front-Line Treatment of High-Risk Diffuse Large B Cell Lymphoma (DLBCL)[NCT03742258]	Phase 1	12 participants (Actual)	Interventional	2019-03-13	Active, not recruiting
Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Tagraxofusp (SL-401) in Combination With HCVAD/Mini-CVD and VENETOCLAX[NCT04216524]	Phase 2	40 participants (Anticipated)	Interventional	2020-05-29	Recruiting
Correlation of Auditory Evoked Brainstem Response Characteristics and Salivary Cortisone Concentration in Noise-exposed Workers[NCT04183361]		100 participants (Anticipated)	Observational	2019-11-01	Enrolling by invitation
Cortisone Injection vs Trigger Point Dry Needling Fin the Treatment of Greater Trochanter Pain Syndrome: A Pilot Study[NCT02639039]	Phase 4	50 participants (Actual)	Interventional	2013-02-28	Completed
Randomized Phase II Trial of Docetaxel With or Without PSA-TRICOM Vaccine in Patients With Castrate-Resistant Metastatic Prostate Cancer[NCT01145508]	Phase 2	10 participants (Actual)	Interventional	2010-08-31	Terminated(stopped due to Poor accrual)
A Phase 1b, Open-Label Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients With Presumed Nonalcoholic Steatohepatitis (NASH)[NCT05117489]	Phase 1	70 participants (Anticipated)	Interventional	2021-11-23	Recruiting
Smart Stop: A Phase II Trial of Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Prior to and With Standard Chemotherapy for Patients With Newly Diagnosed DLBCL[NCT04978584]	Phase 2	60 participants (Anticipated)	Interventional	2022-03-03	Recruiting
A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)[NCT01186328]	Phase 1	6 participants (Actual)	Interventional	2010-08-24	Terminated(stopped due to Enzon Pharmaceuticals decided to end its development of EZN-3042.)
The Use of Bone Marrow Aspirate Concentrate in the Context of Hip Osteoarthritis: A Randomized Controlled Trial[NCT03410355]		6 participants (Actual)	Interventional	2018-02-01	Terminated(stopped due to Health Canada no longer allowed use of BMAC)
A Randomized Clinical Study Comparing Topical 0.05% Clobetasol Propianate in Vaseline With UVA-1 Phototherapy in the Treatment of Vulvar Lichen Sclerosus[NCT01400022]		30 participants (Actual)	Interventional	2010-08-31	Completed
ACADEMIC: A Randomized Phase II Clinical Trial of ADT Combined With Abiraterone or Docetaxel in Metastatic Hormone Sensitive Prostate Cancer[NCT03827473]	Phase 2	1 participants (Actual)	Interventional	2019-02-08	Terminated(stopped due to The trial was closed because the changing standard of care landscape, making this trial not impactful anymore.)
Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol[NCT00991744]	Phase 3	100 participants (Anticipated)	Interventional	2009-01-31	Suspended(stopped due to Sterility problems in DepoCyte production)
Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)[NCT00720109]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2008-07-14	Completed
Influence of Cortisone on QTc-interval[NCT03082339]		105 participants (Actual)	Observational [Patient Registry]	2017-04-01	Completed
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma[NCT02561273]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2015-09-28	Completed
A Prospective, Open, Randomized Controlled Stage II Trial Investigating the Efficacy and Safety of Thymosin Alpha-1 in Treating Moderate to Severe Immune-related Adverse Events[NCT06178146]	Phase 4	40 participants (Anticipated)	Interventional	2023-09-01	Recruiting
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults[NCT04530565]	Phase 3	348 participants (Anticipated)	Interventional	2021-01-25	Recruiting
Phase II Study of Talazoparib With Androgen Deprivation Therapy and Abiraterone in Castration Sensitive Prostate Cancer[NCT04734730]	Phase 2	70 participants (Anticipated)	Interventional	2021-05-04	Recruiting
A Randomized Single-blinded Clinical Trial of the Efficacy of Intra-articular Infiltration of Cingal (Sodium Hyaluronate/Triamcinolone) Versus Cortisone (Triamcinolone) in Patients With Osteoarthritis of the Shoulder.[NCT05408065]		84 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis[NCT04438382]	Phase 2	1 participants (Actual)	Interventional	2021-01-07	Active, not recruiting
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma[NCT03269669]	Phase 2	95 participants (Anticipated)	Interventional	2018-01-23	Recruiting
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Miricorilant Tablet Formulations Following Single and Multiple Oral Doses in Healthy Participants[NCT04672499]	Phase 1	36 participants (Actual)	Interventional	2020-04-27	Completed
A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer[NCT02703623]	Phase 2	196 participants (Actual)	Interventional	2016-05-18	Active, not recruiting
Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia[NCT02199184]	Phase 2	6 participants (Actual)	Interventional	2015-01-14	Completed
Treatment of Children With Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)[NCT00107198]	Phase 2	188 participants (Actual)	Interventional	2006-01-02	Active, not recruiting
Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema[NCT01843530]	Phase 3	31 participants (Actual)	Interventional	2013-11-30	Completed
Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study[NCT00866307]	Phase 1	104 participants (Actual)	Interventional	2009-02-23	Completed
A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia[NCT05761171]	Phase 2	78 participants (Anticipated)	Interventional	2023-11-20	Recruiting
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies[NCT05292664]	Phase 1	92 participants (Anticipated)	Interventional	2023-03-29	Recruiting
Interest of Cryotherapy or Cortisone Aerosol Therapy in Early Post-operative Swallowing Disorders Following Total Thyroidectomy[NCT02855866]		240 participants (Actual)	Interventional	2013-09-03	Completed
A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy for Patients With High Risk Diffuse Large B-Cell Lymphoma[NCT02636322]	Phase 2	60 participants (Actual)	Interventional	2016-03-29	Completed
A Phase I Adaptive Dose, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered CORT125236 in Healthy Subjects, With an Optional Pharmacological Effects [NCT05003713]	Phase 1	82 participants (Actual)	Interventional	2021-08-03	Completed
A Randomized Trial of Cortisone Injection Versus Bone Marrow Aspirate Injection Therapy for Glenohumeral Osteoarthritis[NCT03580148]	Phase 2/Phase 3	34 participants (Actual)	Interventional	2015-10-08	Completed
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia[NCT03488225]	Phase 2	4 participants (Actual)	Interventional	2018-03-28	Terminated(stopped due to the study was closed early due to competing trials)
A Selective Frontline Cabazitaxel Therapeutic Pathway for Castration-Resistant Prostate Cancer With Integrated Biomarkers[NCT02844582]	Phase 2	2 participants (Actual)	Interventional	2017-12-20	Terminated(stopped due to Poor accrual of subjects onto study)
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement[NCT02828358]	Phase 2	78 participants (Actual)	Interventional	2017-04-01	Active, not recruiting
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)[NCT00557193]	Phase 3	218 participants (Actual)	Interventional	2008-01-15	Active, not recruiting
Safety and Efficacy of Adult Adipose-Derived Stem Cell Injections Into Partial Thickness Rotator Cuff Tears[NCT02918136]		18 participants (Actual)	Interventional	2016-12-31	Completed
Phase II Study to Determine the Effects of Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate in Patients Who Are Scheduled for Radical Prostatectomy With Genomic Correlates of Pathological Response[NCT00598858]	Phase 2	0 participants (Actual)	Interventional	2009-01-31	Withdrawn(stopped due to Halted due to zero accrual and lack of funding)
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia[NCT05320380]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2023-08-01	Withdrawn(stopped due to Withdrawn per CS0150757)
A Phase 2, Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Metastatic Prostate Cancer Patients Evaluating a Predetermined Biomarker Signature[NCT03360721]	Phase 2	7 participants (Actual)	Interventional	2018-03-06	Active, not recruiting
A Dose-Finding Phase Ib Study of the Oral BCL-2 Inhibitor Venetoclax (ABT-199) in Combination With Standard Induction Therapy, Dasatinib, Prednisone, (and Rituximab in CD20+ Patients) in Adult Patients With Newly Diagnosed and Relapsed Philadelphia Chromo[NCT04872790]	Phase 1	20 participants (Anticipated)	Interventional	2022-09-02	Recruiting
A Phase 2 Course Determining Study for Men With Hormone-Naïve Metastatic Prostate Cancer (HNMPCa)[NCT03821792]	Phase 2	60 participants (Anticipated)	Interventional	2019-07-22	Active, not recruiting
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma[NCT04759586]	Phase 3	244 participants (Anticipated)	Interventional	2021-10-05	Recruiting
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas[NCT03984448]	Phase 2/Phase 3	363 participants (Anticipated)	Interventional	2019-10-22	Active, not recruiting
Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma[NCT00501826]	Phase 2	160 participants (Anticipated)	Interventional	2007-07-11	Recruiting
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)[NCT02420717]	Phase 2	11 participants (Actual)	Interventional	2015-07-15	Terminated(stopped due to Study was closed early due to low accrual and lack of response.)
Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)[NCT01331018]	Phase 1	3 participants (Actual)	Interventional	2012-02-22	Active, not recruiting
Open Label Pharmacodynamic Study of Abiraterone Acetate in the Treatment of Metastatic, Castration Resistant Prostate Cancer[NCT01503229]	Phase 2	32 participants (Actual)	Interventional	2012-12-31	Completed
Role of Microbiome in the Realm of Immune-Checkpoint Inhibitor Induced GI Complications In Cancer Population[NCT03819296]	Phase 1/Phase 2	800 participants (Anticipated)	Interventional	2021-02-21	Recruiting
A Randomized Gene Fusion Stratified Phase 2 Trial of Abiraterone With or Without ABT-888 for Patients With Metastatic Castration-Resistant Prostate Cancer[NCT01576172]	Phase 2	159 participants (Actual)	Interventional	2012-03-30	Completed
Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-CHOP in a Cohort of Patients With DLBCL/tFL/ High Grade B-NHL[NCT03704714]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2018-11-20	Suspended(stopped due to Protocol being amended for stats/accrual changes as per PI)
Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL)[NCT05032183]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2022-02-17	Recruiting
Intra-articular Botulinum Toxin Type-A in Knee Osteoarthritis - a Randomized, Cortisone Controlled, Double Blind Study.[NCT00279903]	Phase 1	62 participants (Actual)	Interventional	2005-11-30	Completed
Conservative Treatment of Trigger Finger: Outcomes of a Randomized Controlled Trial[NCT05837286]		146 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
Congenital Adrenal Hyperplasia: Innovative Once Daily Dual Release Hydrocortisone Treatment[NCT03760835]	Phase 4	150 participants (Anticipated)	Interventional	2016-08-11	Recruiting
Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia[NCT01771328]	Phase 2	20 participants (Anticipated)	Interventional	2013-02-28	Recruiting
Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis: a Randomized Controlled Study[NCT02196155]		54 participants (Anticipated)	Interventional	2016-07-31	Recruiting
Effectiveness of Facet Joint Infiltration in Low Back Pain[NCT01447160]	Phase 3	60 participants (Anticipated)	Interventional	2011-10-31	Not yet recruiting
High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases[NCT00716066]	Phase 2	80 participants (Anticipated)	Interventional	2008-06-30	Recruiting
The Effect of Low-dose Corticosteroids and Theophylline on the Risk of Acute Exacerbations of COPD: the TASCS Randomised Clinical Trial[NCT02261727]	Phase 4	1,670 participants (Actual)	Interventional	2014-06-30	Completed
Comparison of IntraArticular Platelet-Rich-Plasma to Corticosteroid Injections for Patients With Zygapophyseal Joint (Z-Joint) Low Back Pain Confirmed by Dual Intra-Articular Local Anesthetic Injections: A Triple Blinded Randomized Controlled Trial[NCT05188820]		50 participants (Anticipated)	Interventional	2022-04-01	Recruiting
Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection: A Randomized Controlled Double-Blind Study[NCT04126278]	Phase 4	150 participants (Anticipated)	Interventional	2020-12-01	Recruiting
A Pilot Phase I/II Study to Evaluate the Effects of Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients With Biochemical Relapse[NCT00879619]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Terminated due to slow accrual.)
A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV[NCT04139304]	Early Phase 1	15 participants (Anticipated)	Interventional	2021-05-24	Recruiting
A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate Cancer[NCT02522715]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2015-10-13	Active, not recruiting
MK-3475 in Combination With Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma[NCT02541565]	Phase 1	30 participants (Actual)	Interventional	2015-11-24	Completed
Radiation Enhancement of Local and Systemic Anti-Prostate Cancer Immune Responses[NCT03649841]	Phase 2	10 participants (Actual)	Interventional	2020-06-29	Terminated(stopped due to Terminated due to low accrual.)
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer[NCT03678025]	Phase 3	1,273 participants (Anticipated)	Interventional	2018-09-24	Recruiting
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial[NCT03419234]	Phase 2	223 participants (Actual)	Interventional	2018-04-26	Active, not recruiting
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas[NCT03113500]	Phase 2	48 participants (Actual)	Interventional	2017-05-25	Active, not recruiting
A Pre-Operative Study to Assess the Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence[NCT03279250]	Phase 2	86 participants (Actual)	Interventional	2017-10-13	Completed
An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)[NCT04752163]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2021-03-25	Completed
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations[NCT02883049]	Phase 3	5,937 participants (Actual)	Interventional	2012-02-29	Active, not recruiting
A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62[NCT05409027]	Phase 1	12 participants (Actual)	Interventional	2021-08-05	Active, not recruiting
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia[NCT06124157]	Phase 3	680 participants (Anticipated)	Interventional	2024-01-22	Not yet recruiting
Multiple Dose Safety, Tolerability, Plasma and Cerebrospinal-Fluid Pharmacokinetic Study of Oral Doses of CORT113176[NCT04994743]	Phase 1	16 participants (Actual)	Interventional	2021-07-13	Completed
A Phase Ib Trial of Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma[NCT04850495]	Phase 1	24 participants (Anticipated)	Interventional	2021-11-16	Suspended(stopped due to Pending amendment)
A Pilot Study: Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas[NCT00624416]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2007-10-31	Completed
A Phase 2 Study of Loncastuximab Tesirine and Rituximab (Lonca-R) Followed by DA-EPOCH-R in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma[NCT05600686]	Phase 2	24 participants (Anticipated)	Interventional	2023-05-24	Recruiting
Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)[NCT03808610]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2019-04-03	Recruiting
A Multicenter, Randomized, Double-blind, Parallel Controlled Clinical Study on the Efficacy and Safety of Compound E Jiao Jiang(cEJJ）in the Treatment of Postpartum Anemia[NCT06175117]	Phase 4	360 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Randomized, Controlled, Multi-Centre Trial on the Effects of Dual-release Hydrocortisone Preparations Versus Conventional Glucocorticoid Replacement Therapy in Patients Affected by Primary and Secondary Adrenal Insufficiency. DREAM Trial.[NCT02277587]	Phase 4	89 participants (Actual)	Interventional	2014-03-31	Completed
A Phase 1, Open-label, Single-dose, Randomized, Crossover Study in Healthy Subjects of the Effects of Co-administration With Food on Exposure, and to Determine the Within-subject Variability in Exposure, to Relacorilant and Its Metabolites[NCT03442621]	Phase 1	30 participants (Actual)	Interventional	2018-01-16	Completed
Phase 2 Study of CJNJ-67652000 (Niraparib/Abiraterone Acetate Fixed-Dose Combination) and Prednisone for Metastatic Castration-Resistant Prostate Cancer Associated With SPOP Mutation With or Without Homologous Recombination Deficiency[NCT05689021]	Phase 2	30 participants (Anticipated)	Interventional	2023-07-07	Recruiting
Phase II Trial of Primary Radiotherapy With Androgen Ablation With or Without Adjuvant Niraparib for Selected High-Risk Locoregional Prostate Cancer[NCT04947254]	Phase 2	200 participants (Anticipated)	Interventional	2021-08-05	Recruiting
A Randomized Phase II Pilot of Tailored Prednisone Reduction Versus Usual Care for the Treatment of Hyperglycemia During R-CHOP Chemotherapy[NCT03505762]	Phase 2	80 participants (Anticipated)	Interventional	2018-07-19	Recruiting
Extension Study of Protocol RC-001b- Safety and Efficacy of Adult Adipose-Derived Stem Cell Injection Into Partial Thickness Rotator Cuff Tears[NCT04077190]		15 participants (Actual)	Interventional	2019-08-01	Completed
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) +/- Rituximab (R) + Tafasitamab-cxix for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative (Ph-) B-cell Lymphoblastic Lymphoma/Leuke[NCT05453500]	Phase 2	30 participants (Anticipated)	Interventional	2023-03-27	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Event-free Survival

Events were defined as any of the following: (1) unable to achieve either morphologic complete remission (CR) or MRD- by MFC, (2) relapse after CR, (3) MRD recurrence after achieving MRD-, or (4) death from any cause. (NCT03023046)
Timeframe: Up to 2 years

Intervention	Percentage of Participants (Number)
Treatment (Chemotherapy)	32

Intervention	Participants (Count of Participants)				Participants (Count of Participants)
	MFC-72545885		MFC-72545886	CMR72545885	HTS-72545885	HTS-72545886
	Achieve within 4 cycles	Not achieved within 4 cycles
Ph+ Subjects	20
Ph- Subjects	9
Ph+ Subjects	11
Ph+ Subjects	17
Ph+ Subjects	8
Ph- Subjects	6
Ph+ Subjects	16
Ph- Subjects	16

Intervention	Participants (Count of Participants)
	Complete response (CR), partial response (PR) or stable disease (SD) without allograft loss	Progressive Disease (PD) without allograft loss
Nivolumab, Tacrolimus, and Prednisone	0	8

Intervention	Participants (Count of Participants)
	Experienced allograft loss	Did not experience allograft loss
Ipilimumab, Nivolumab, Tacrolimus, and Prednisone	3	3

Intervention	Change in Bayley's score (Mean)
Arm I (Chemotherapy, Immunoglobulin Therapy)	117.5
Arm II (Chemotherapy, Observation)	100.75

Intervention	Change in VABS score (Mean)
Arm I (Chemotherapy, Immunoglobulin Therapy)	84.53
Arm II (Chemotherapy, Observation)	144.73

Intervention	3 year EFS (Number)
Arm I (Chemotherapy, Immunoglobulin Therapy)	92.3
Arm II (Chemotherapy, Observation)	96.0

Intervention	Participants (Count of Participants)
Arm I (Calaspargase Pegol 2100)	2
Arm II (Calaspargase Pegol 2500)	2
Arm III (Pegaspargase 2500)	4

Intervention	Percentage of participants (Number)
Arm I (Calaspargase Pegol 2100)	92.4
Arm II (Calaspargase Pegol 2500)	97.6
Arm III (Pegaspargase 2500)	94.1

Intervention	Percentage of participants (Number)
Arm I (Calaspargase Pegol 2100)	72.35
Arm II (Calaspargase Pegol 2500)	80.8
Arm III (Pegaspargase 2500)	79.34

Intervention	Percentage of participants (Number)
Arm I (Calaspargase Pegol 2100)	65.2
Arm II (Calaspargase Pegol 2500)	81
Arm III (Pegaspargase 2500)	72.5

Intervention	percentage of patients (Number)
	Level at least 0.1 IU/mL day 4	Level at least 0.1 IU/mL day 15	Level at least 0.1 IU/mL day 22	Level at least 0.1 IU/mL day 29	Level at least 0.4 IU/mL day 4	Level at least 0.4 IU/mL day 15	Level at least 0.4 IU/mL day 22	Level at least 0.4 IU/mL day 29
Arm I (Calaspargase Pegol 2100)	0	98.4	98.2	94.9	0	75.8	37.5	13.6
Arm II (Calaspargase Pegol 2500)	0	100	100	95.0	0	95.0	62.5	27.5
Arm III (Pegaspargase 2500)	0	100	95.1	28.6	0	93.0	14.6	0

Intervention	mIU/mL (Median)
	Plasma Asparaginase Concentration- Consolidation	Plasma Asparaginase Concentration- Induction
Arm I (Calaspargase Pegol 2100)	575.9	271.6
Arm II (Calaspargase Pegol 2500)	617.2	339.6
Arm III (Pegaspargase 2500)	562.1	72.8

Intervention	hours (Mean)
	Asparaginase half-life during Consolidation	Asparaginase half-life during Induction
Arm I (Calaspargase Pegol 2100)	415.8	305.1
Arm II ( Calaspargase Pegol 2500)	355.9	321.5
Arm III (Pegaspargase 2500)	117.2	126.9

Intervention	ug/mL (Mean)
	CSF asparagine concentration (ug/mL)	Plasma asparagine concentration (ug/mL)
Arm I (Calaspargase Pegol 2100)	0.2	0.2
Arm II (Calaspargase Pegol 2500)	0.19	0.25
Arm III (Pegaspargase 2500)	0.26	0.83

Intervention	Percentage of participants (Number)
	Alergic Reaction - Consolidation	Alergic Reaction - Delayed Intensification I	Alergic Reaction - Interim Maintenance I	CNS - Consolidation	CNS - Delayed Intensification I	CNS - Interim Maintenance I	Hyperbilirubinemia - Consolidation	Hyperbilirubinemia - Delayed Intensification I	Hyperbilirubinemia - Interim Maintenance I	Hyperglycemia - Consolidation	Hyperglycemia - Delayed Intensification I	Hyperglycemia - Interim Maintenance I	Hyperlipidemia - Consolidation	Hyperlipidemia - Delayed Intensification I	Hyperlipidemia - Interim Maintenance I	% patients w/INR increase - Consolidation	% pts w/INR increase - Delayed Intensification I	% patients w/INR increase - Interim Maintenance I	Pancreatitis - Consolidation	Pancreatitis -Delayed Intensification I	Pancreatitis - Interim Maintenance I	% pts w/prolongation of APT time - Consolidation	% pts w/prolongation APT time -Delayed Intension I	%pts w/prolongation APT time-Interim maintenance I	Thrombosis - Consolidation	Thrombosis - Delayed Intensification I	Thrombosis - Interim Maintenance I
Arm I (Calaspargase Pegol 2100)	20.4	4.4	0.0	0.0	0.0	0.0	53.1	28.9	41.3	44.9	44.4	34.8	2.0	2.2	2.2	6.1	6.7	2.2	10.2	2.2	2.2	8.2	8.9	6.5	0.0	2.2	0.0
Arm II (Calaspargase Pegol 2500)	27.3	0.0	0.0	0.0	3.8	0.0	45.5	38.5	27.6	42.4	61.5	44.8	3.0	0.0	3.4	3.0	3.8	0.0	6.1	7.7	3.4	9.1	26.9	6.9	0.0	0.0	0.0
Arm III (Pegaspargase 2500)	23.3	0.0	2.1	0.0	2.6	0.0	30.2	10.5	33.3	46.5	36.8	33.3	7.0	0.0	2.6	7.0	0.0	2.6	7.0	0.0	2.6	7.0	18.4	7.7	2.3	0.0	0.0

Intervention	Participants (Number)
	Abdominal pain	Acute kidney injury	Alanine aminotransferase increased	Anemia	Anorexia	Aspartate aminotransferase increased	Atrial fibrillation	Bladder spasm	Bronchial infection	CD4 lymphocytes decreased	CPK increased	Carbon monoxide diffusing capacity decreased	Colitis	Creatinine increased	Cystitis noninfective	Dehydration	Depression	Diarrhea	Disseminated intravascular coagulation	Dizziness	Duodenal perforation	Dysphagia	Dyspnea	Electrocardiogram QT corrected interval prolonged	Fatigue	Febrile neutropenia	Fecal incontinence	Gastrointestinal disorders - Other, specify	Generalized muscle weakness	Hematuria	Hiccups	Hyperglycemia	Hypoalbuminemia	Hypocalcemia	Hypokalemia	Hyponatremia	Hypophosphatemia	Hypotension	Infections and infestations - Other, specify	Jejunal perforation	Left ventricular systolic dysfunction	Leukocytosis	Lung infection	Lymphocyte count decreased	Mucosal infection	Mucositis oral	Multi-organ failure	Myalgia	Myocardial infarction	Nausea	Neutrophil count decreased	Obstruction gastric	Pain	Paronychia	Peripheral motor neuropathy	Platelet count decreased	Pneumonitis	Recurrent laryngeal nerve palsy	Respiratory failure	Sepsis	Sinus tachycardia	Sinusitis	Small intestinal obstruction	Stoma site infection	Syncope	Urinary tract infection	Urinary tract pain	Urine output decreased	Vasovagal reaction	Visceral arterial ischemia	Vomiting	Weight loss	White blood cell decreased
Ph I: R-CHOP+Vorinostat (400mg D1-9)	1	0	0	4	1	0	0	0	0	0	0	0	1	1	0	2	1	2	1	1	0	0	0	1	3	3	0	0	2	1	0	0	1	1	2	0	1	0	1	0	0	0	0	4	0	1	1	1	0	1	8	0	0	0	1	4	0	0	0	3	0	0	0	0	0	0	0	1	0	1	0	0	7
Ph II: R-CHOP+Vorinostat	3	1	1	22	2	1	1	1	1	1	1	1	0	0	1	4	0	2	0	0	1	1	1	1	9	24	1	1	2	0	1	4	3	0	8	6	2	3	3	1	1	1	4	20	1	3	0	2	2	3	37	1	1	1	0	22	1	1	1	11	1	1	1	1	4	3	2	0	1	0	2	3	32

Intervention	cells/mm^3 (Median)
	End of cycle 2	Treatment discontinuation	6-month follow-up	12-month follow-up
Phase I: VR-CHOP, Dose Level 1	-172	-81	-16	128
Phase I: VR-DA-EPOCH, Dose Level 1	35.5	-164.5	-56	604
Phase I: VR-DA-EPOCH, Dose Level 2	-115	211	275	154

Intervention	IU/mL (Median)
	End of Cycle 2	At treatment discontinuation	6-month follow-up	12-month follow-up
Phase I: VR-DA-EPOCH, Dose Level 1	0	0	0	0
Phase I: VR-DA-EPOCH, Dose Level 2	-2436.1	-1.92	-1.92	-1.15
Phase II, DA-R-EPOCH	0	-0.28	0	-2.7
Phase II, VR-DA-EPOCH	-0.61	-2.9	-1.55	-0.56

Intervention	percentage of participants (Number)
	Death	Life-threatening	Severe	Moderate	Mild
Phase II: DA-R-EPOCH	20.0	28.9	31.1	17.8	0
Phase II: VR-DA-EPOCH	28.9	37.8	20.0	8.9	2.2

Intervention	Liter/hour (Mean)
	Doxorubicin	Etoposide	Vincristine
Phase I: VR-DA-EPOCH, Dose Level 1	78.6	3.0	22.4
Phase I: VR-DA-EPOCH, Dose Level 2	76.0	2.4	16.8

cortisone

Cross-References

Synonyms (160)

Research Excerpts

Overview

Effects

Actions

Treatment

Roles (2)

Drug Classes (9)

Pathways (21)

Protein Targets (63)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (106)

Molecular Functions (49)

Ceullar Components (46)

Bioassays (167)

Research

Studies (17,594)

Study Types

Clinical Trials (145)

Trial Overview

Trial Outcomes

Event-free Survival

Number of Participants With Adverse Events

Number of Participants With Morphological Complete Response Rate

Overall Survival

Number of Participants With Complete Measurable Residual Disease (MRD) Response Rate

Duration of Overall Survival After Receiving Nivolumab, Tacrolimus, and Prednisone

Duration of Progression-free Survival After Receiving Nivolumab, Tacrolimus, and Prednisone

Number (and Percentage) of Outcome Responses After Receiving Nivolumab, Tacrolimus, and Prednisone

Rate of Allograft Loss After Receiving Ipilimumab, Nivolumab, Tacrolimus, and Prednisone

3-year Progression-free Survival Rate

Overall Survival Rate at 3 Years

Proportion of Patients With Complete Response

Proportion of Patients With Response

Functional Outcome as Assessed by Age-appropriate Neuropsychological Testing

Motor Coordination as Assessed by Neurological Examination and Vineland Adaptive Behavior Scale (VABS)

Number of Responders

Tumor Outcome in Terms of Event-free Survival (EFS) Rate Defined as a Relapse or Progression of Neuroblastoma, a Second Malignancy, or Death

Tumor Outcome in Terms of Overall Survival (OS) Rate

Continuous Complete Remission (CCR) Rate

Overall Survival (OS)

Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation

12-month PFS (Progression Free Survival) of Treatment With Ixazomib in Combination With DA-EPOCH-R (Phase II)

To Determine the Recommended Phase II Dose (RP2D) of Ixazomib in Combination With DA-EPOCH-R.

Immunogenicity

Percentage of Participants With Complete Remission at the End of Induction

Percentage of Participants With Event-free Survival (EFS)

Percentage of Participants With Minimal Residual Disease (MRD)<0.01% at the End of Induction

Asparaginase Level

Pharmacodynamics (PD)

Pharmacokinetics (PK) (Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285) Compared to Pegaspargase During Induction and Consolidation Therapy)

Plasma and CSF Concentrations of Asparagine in ug/ml

Toxicities During Post Induction Intensification Therapy (All Grades)

Overall Survival (Phase II)

Progression-free Survival (Phase II)

Response Rate (Complete Response [CR]+Partial Response [PR]) (Phase II)

Safe Dose of Vorinostat to be Used in Combination With R-CHOP Assessed by CTCAE Version 4.0 (Phase I)

Toxicity of Vorinostat-R-CHOP in Patients With Newly Diagnosed DLBCL

Event-free Survival (EFS) (Phase II)

Overall Survival (OS) (Phase II)

Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)

Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)

Change in CD8 Cell Counts (Phase I)

Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)

Changes in Absolute CD4 Cell Counts (Phase I)

Changes in Epstein-Barr Virus (EBV) Viral Load

Changes in Human Herpes Virus (HHV)-8 Viral Load

Changes in Human Herpes Virus (HHV)-8 Viral Load

Changes in Human Immunodeficiency Virus (HIV) Viral Load

Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)

Pharmacokinetic Clearance (Phase I)

Tumor Response (Phase I)

Change in Functional Assessment of Cancer Therapy-Neurotoxicity Trial Outcome Index (FACT-Ntx TOI) Score From Baseline to Cycle 12

Overall Survival

Progression-Free Survival (PFS)

Very Good Partial Response (VGPR) Rate

Intervention	percentage of participants (Number)
	Complete response	Partial Response
Phase I: Arm C (VR-CHOP) Dose Level 1	100	0
Phase I: VR-DA-EPOCH, Dose Level 1	83.3	16.7
Phase I: VR-DA-EPOCH, Dose Level 2	83.3	16.7

Intervention	percent probability (Number)
ARM I and ARM II (Combination Chemotherapy)	91.45
ARM III and ARM IV (Combination Chemotherapy)	85.78

Intervention	percent probability (Number)
ARM I (Combination Chemotherapy)	91.76
ARM II (Combination Chemotherapy)	90.53
ARM III (Combination Chemotherapy)	86.06
ARM IV (Combination Chemotherapy)	84.89

Intervention	percent probability (Number)
ARM I and ARM III (Combination Chemotherapy)	82.96
ARM II and ARM IV (Combination Chemotherapy)	88.30

Intervention	percent probability (Number)
ARM I (Combination Chemotherapy)	89.01
ARM II (Combination Chemotherapy)	90.53
ARM III (Combination Chemotherapy)	78.07
ARM IV (Combination Chemotherapy)	86.46

Intervention	percent probability (Number)
	Intermediate Risk	High Risk
ARM II (Combination Chemotherapy)	1.08	0
ARM IV (Combination Chemotherapy)	0.85	3.45

Intervention	percent probability (Number)
	Low Risk	Intermediate Risk	High Risk
ARM I (Combination Chemotherapy)	1.85	1.16	3.64
ARM III (Combination Chemotherapy)	1.92	9.1	6.52

Intervention	percent probability (Number)
	High Risk	Induction Failure
ARM II (Combination Chemotherapy)	85.0	100

Intervention	percent probability (Number)
	Standard Risk	High Risk
ARM I (Combination Chemotherapy)	87.4	85.1

Intervention	Participants (Count of Participants)
	No nodal metastases	Nodal metastases
Treatment (Neoadjuvant Chemotherapy)	13	7